Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore, Novartis Venture Sees Trials For Dengue Drug In 2011

This article was originally published in PharmAsia News

Executive Summary

Swiss pharmaceutical Novartis said its partnership with Singapore's government to seek cures for diseases plaguing poor countries could lead to clinical trials for a drug to treat dengue fever as early as 2011. The company and the government jointly created the Novartis Institute for Tropical Diseases devoted to finding cures for dengue, malaria and tuberculosis. Novartis said it is developing new dengue cures to replace one halted last October because of human safety concerns. The institute plans to sell drugs it brings to market in poor nations at cost. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel